Zepbound® Tirzepatide

Zepbound® is an injectable prescription medicine that may help adults with obesity, weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound® should be used with a reduced-calorie diet and increased physical activity.

Recently, the FDA approved Zepbound for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical Care in the FDA’s Center for Drug Evaluation and Research. “This is a major step forward for patients with obstructive sleep apnea.”

OSA occurs when a person’s upper airway becomes blocked, causing pauses in breathing during sleep. While OSA can affect anyone, it is more common in people who have overweight or obesity. Zepbound works by activating receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food intake. By reducing body weight, studies show that Zepbound also improves OSA.

Zepbound® works differently than other obesity management medications by activating 2 hormone receptors. It reduces appetite and food intake.*

* Hormone receptors of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

Overall change in body weight after 17 months* in adults without diabetes was a loss of 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo. Average starting weights were 226.8 lbs for 5 mg, 233.3 lbs for 10 mg, 232.8 lbs for 15 mg, and 231.0 lbs for placebo.

*Treatment or placebo included a reduced-calorie diet and increased physical activity.

Individual results may vary.
Data collected in a less rigorous study so findings are less certain. Factors beyond studied medications may have contributed to weight loss.

Zepbound is not for cosmetic weight loss.

¶Along with diet and exercise.

**In a 72-week study of adults without diabetes with obesity or overweight and weight-related medical problems, participants on Zepbound MTD (10 mg or 15 mg, the max dose a participant could tolerate) experienced on average a 20.2% (50 Ibs) weight loss compared to an average of 13.7% (33 Ibs) weight loss for participants on Wegovy MTD (1.7 mg or 2.4 mg, the max dose a participant could tolerate). Average starting weights were 248.4 Ibs for Zepbound MTD and 250 Ibs for Wegovy MTD.

MTD=maximum tolerated dose.

Wegovy® is a registered trademark of Novo Nordisk A/S.

Click the button below and complete the form to receive 3 complimentary Fat Burner Shots with your purchase!